Why clinical trials are becoming central to healthtech portfolios?
Healthtech investors increasingly recognise that evidence-backed solutions generate superior returns compared to products lacking validated outcomes. This shift prioritises companies generating credible clinical data over those relying primarily on technological innovation without proven health impacts. The industry-wide move toward value-based care necessitates solutions with demonstrated effectiveness, making empirical results a...







